Video yükleniyor...

Video Yüklenemedi

Ana Sayfaya Dön

Today we’re announcing the $600M Formation Bio Drug Development Accelerator Fund. linhao and I started Formation Bio because we believed the biggest bottleneck in bringing new medicines to patients wasn’t drug discovery, but drug development. As AI dramatically accelerates discovery, that bottleneck is only becoming more acute. Without the...

245,735 görüntüleme • 20 gün önce •via X (Twitter)

51 Yorum

Dryden profil fotoğrafı
Dryden20 gün önce

@lintaho @formationbio Congratulations Ben

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @drydenwtbrown!

Sam Davis profil fotoğrafı
Sam Davis20 gün önce

@lintaho @formationbio Love to see this - disrupting tthe status quo:. Keep dominating Ben.

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks so much @SamDavisBio!

Lauren Boles profil fotoğrafı
Lauren Boles20 gün önce

@lintaho @formationbio Congrats team!! Such important work

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @LaurenBoles_!

Ben Miles profil fotoğrafı
Ben Miles20 gün önce

@lintaho @formationbio Proud of the team!

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @BenNMiles -- grateful to get to work together!

Lilly Schade profil fotoğrafı
Lilly Schade20 gün önce

@lintaho @formationbio exciting

Han Seoul Ohno profil fotoğrafı
Han Seoul Ohno20 gün önce

@lintaho @formationbio Congratulations Ben

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @hanseoulohno!

Raphael profil fotoğrafı
Raphael20 gün önce

@lintaho @formationbio Huge, congrats Ben

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @0xRapha!

Sherad Louis-Charles 🇺🇸 profil fotoğrafı
Sherad Louis-Charles 🇺🇸20 gün önce

@lintaho @formationbio Congrats. People are underestimating how large biotech will become.

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @slouischarles! Yes, especially drugs that prevent disease and help you function longer and healthier.

John Evans profil fotoğrafı
John Evans20 gün önce

@lintaho @formationbio Congrats Ben! Awesome

richard profil fotoğrafı
richard20 gün önce

@lintaho @formationbio Let’s go congrats Ben and Linhao!!

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @richardzphotoz — really enjoyed working with you on this!

Alexey Kadet profil fotoğrafı
Alexey Kadet20 gün önce

@lintaho @formationbio Interesting

Rushabh Sheth profil fotoğrafı
Rushabh Sheth20 gün önce

@lintaho @formationbio Tanishq Mathew Abraham said on MTS that testing in patients can move on a much quicker timeline than developing drugs from scratch. So this is great news.

Tom Hollands profil fotoğrafı
Tom Hollands20 gün önce

@lintaho @formationbio It's been such a joy learning about Formation Bio and your new fund, working with @lintaho and Lily, and seeing this come to life. congrats on the success and thanks for partnering with us!

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @tdoggyholhol -- enjoyed working with you and the new media team on this!

Tom Hollands profil fotoğrafı
Tom Hollands20 gün önce

@lintaho @formationbio our pleasure :)

Mehreen Malik profil fotoğrafı
Mehreen Malik20 gün önce

@lintaho @formationbio Congrats Ben!

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @MehreenNMalik!

brexton profil fotoğrafı
brexton20 gün önce

@lintaho @formationbio LETS GO BEN!!

Bo Wang profil fotoğrafı
Bo Wang20 gün önce

@lintaho @formationbio Congratulations Ben!

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks so much @BoWang87 ! And congrats on all the amazing progress at @Xaira_Thera. Look forward to finding programs to work on together in the future!

Bo Wang profil fotoğrafı
Bo Wang20 gün önce

@lintaho @formationbio @Xaira_Thera Thanks Ben! Will DM you and set up a quick call if possible

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio @Xaira_Thera Great! looking forward to it!

Toby Tung profil fotoğrafı
Toby Tung20 gün önce

@lintaho @formationbio Congrats Ben! Will the Fund look at Phase 1/2 assets out of China? A lot of Chinese biotechs have clean early clinical data but no capital or infrastructure to run global trials — that seems like exactly the “stalled in the pipeline” pool you’re describing.

Vikas Agarwal profil fotoğrafı
Vikas Agarwal20 gün önce

@lintaho @formationbio Congrats !

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks @VikasAgarwal44!

hinata_ji profil fotoğrafı
hinata_ji20 gün önce

@lintaho @formationbio Your co-founder is the real Zhang et al

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio He’s the best!

Fabio Boniolo profil fotoğrafı
Fabio Boniolo20 gün önce

@lintaho @formationbio Congrats! Great initiative

Ben Liu profil fotoğrafı
Ben Liu20 gün önce

@lintaho @formationbio Thanks Fabio!

Julia Li profil fotoğrafı
Julia Li20 gün önce

@lintaho @formationbio amazing

AlphaOnly profil fotoğrafı
AlphaOnly20 gün önce

@lintaho @formationbio @grok how can one invest in this fund and how might it help any particular small biotechs with their own research?

Gravity Research profil fotoğrafı
Gravity Research20 gün önce

@lintaho @formationbio massive war chest

Yuanhao Qu profil fotoğrafı
Yuanhao Qu20 gün önce

@lintaho @formationbio Congrats Ben!

Chris Leiter profil fotoğrafı
Chris Leiter20 gün önce

@lintaho @formationbio congrats, Ben! great for the ecosystem

Avraham Berkowitz profil fotoğrafı
Avraham Berkowitz20 gün önce

@vintweeta @lintaho @formationbio Congrats Ben! You can double the amount of FDA approved drugs in the next two years.

Adam Gefkovicz profil fotoğrafı
Adam Gefkovicz20 gün önce

@lintaho @formationbio You are truly one of the good guys. Congratulations brother!

AGTP profil fotoğrafı
AGTP20 gün önce

@lintaho @formationbio That gap between discovery and development is exactly what we're seeing Claude solve. We actually detailed the concrete results here:

Boardy profil fotoğrafı
Boardy20 gün önce

@lintaho @formationbio there's someone running translational and clinical development on a small molecule already in first-in-human and phase 2 trials. couldn't get a dm through so tap below if you want that intro

Amee Kapadia profil fotoğrafı
Amee Kapadia20 gün önce

@lintaho @formationbio Go Ben!!

Chengwei Luo profil fotoğrafı
Chengwei Luo20 gün önce

@lintaho @formationbio Exciting!

BIGGLY BILL BRASKY ACC/⚔️🪽 profil fotoğrafı
BIGGLY BILL BRASKY ACC/⚔️🪽20 gün önce

@lintaho @formationbio Wait, was that a semi-formal beanie?

Mansi profil fotoğrafı
Mansi20 gün önce

@lintaho @formationbio Congrats!!!

Aniq Rahman profil fotoğrafı
Aniq Rahman20 gün önce

@lintaho @formationbio Congrats man! Very exciting

Benzer Videolar

NEW episode! Drug development has never been more expensive, in terms of output per dollar spent. This trend, called Eroom’s law, is surprising, considering the incredible technological advances in drug discovery, from genome sequencing to engineering to microscopy. On a new episode of the Works in Progress podcast, Ben Southwood and I talk to Ruxandra Teslo 🧬 about why this has happened and what can be done about it. We discuss how: • AI isn’t a magic bullet for drug discovery. Predictive models lack the physical human data, like individual variation and rare side effects, that can only be generated by actually running real-world clinical trials. • As scientists invent more effective drugs, it becomes harder to discover new treatments that can surpass past successes. This is known as the "Better than the Beatles" problem. • Biotech companies are increasingly moving their "first-in-human" trials to Australia because its simpler regulations allow researchers to test drug safety faster and cheaper than in the US. • Clinical trials can be made more efficient with various reforms including: embracing platform trials, allowing researchers to select from independent ethics boards, expanding the funding and validation of surrogate endpoints, increasing transparency by releasing regulatory correspondence from failed companies, and much more. Timestamps: 00:00:00 Eroom’s law and the paradox of drug development 00:08:03 How clinical trials actually work 00:10:23 The power and controversy of surrogate endpoints 00:14:01 How historical patent laws influenced trial timelines 00:22:46 The Australia advantage and regulatory drag 00:29:08 Institutional review boards (IRBs) and bureaucratic drag 00:32:21 Open science and successful reforms 00:41:49 Our wishlist for clinical trial reforms, and which reforms we *don’t* like 00:53:48 Why AI isn’t a magic bullet for drug discovery

Saloni

109,256 görüntüleme • 6 ay önce

I am currently fundraising to build the pharma company of the future. Please email me at [email protected] if you are interested (angel checks + VC welcome). Advances in AI + robotics now enable a ‘single’ human operator to carry out the entire scientific discovery process for a new drug, while costing orders of magnitude less than usual. As proof, I developed two new drugs by myself, with zero outside investment, and assistance only from frontier AI models and liquid-handling robotics. PAC-832 is the world’s first selective GalR1 antagonist for Alzheimer’s disease. PAC-3310 is a new selective M4 agonist for schizophrenia, improving on the selectivity profile of the breakthrough drug Cobenfry (which spearheaded the $14B acquisition of its developer Karuna Therapeutics). This level of efficiency is unprecedented and will enable me to generate >40x more clinical-stage drugs (per dollar spent) than a typical pharma company. Pfizer currently has the most clinical-stage drugs at 137. I will be able to reach 10 clinical-stage drugs within 2 years, then surpass Pfizer within the next 5 years. This plan is contingent on me optimizing one more set of studies known as ‘IND-enabling studies,’ which are required by international regulations to be done prior to clinical trials. This involves me (1) building out my own GMP drug manufacturing facility in SF, and (2) optimizing GLP toxicity studies, which I will be doing in China for cost reasons. Both these things are critical to keep overall costs low and require significant resources, which is why I need to raise money, but are eminently doable. I expect them to take 1-2 years in total. After that, my optimized drug synthesis-to-clinical testing pipeline will be done, and I will start turning the flywheel. The long-term, hardest, yet most important task will be optimizing the clinical trials themselves. In short, I intend to accomplish this by launching the most comprehensive, worldwide site search campaign that I can muster. Once the clinical trials are optimized, then I can finally close the loop on the make -> test -> iterate cycle whose speed dictates progress in drug discovery. The 1950-60s are commonly referred to as the ‘golden age of drug discovery’ due to the large number of transformative medicines that emerged from that era. The key to their success was their tight clinical feedback loop - new drugs were synthesized and rapidly tested in the clinic within 1 year. Today, this process takes 10x as long. Enabled by new technologies like AI and robotics, I strongly believe it is possible to bring back the old level of speed and efficiency. A new golden age of drug discovery is on the horizon, and Pace Pharmaceuticals is its herald.

Douglas Yao

185,386 görüntüleme • 2 ay önce